0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

Angiotensin Converting Enzyme Inhibitors: The End of End-Stage Renal Disease?

Peter U. Feig, MD; and Gale H. Rutan, MD, MPH
[+] Article and Author Information

Requests for Reprints: Peter U. Feig, MD, 448 Scaife Hall, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.


University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania


Ann Intern Med. 1989;111(6):451-453. doi:10.7326/0003-4819-111-6-451
Text Size: A A A
This excerpt has been provided in the absence of an abstract.

More than 30 000 persons annually develop end-stage renal disease as a result of inexorably progressive renal insufficiency. Because of successful development and funding of maintenance therapy, over 120 000 patients live either on chronic dialysis or with renal allografts. The program has high morbidity and costs about $3 billion per year, that is, approximately $25 000 per patient. Further successes in prolonging life on maintenance therapy without affecting the rate of development of renal failure will result in further increases in this number, with the fastest growth among persons over age 65 (1). Arresting the progression of renal deterioration

...

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant Published online Aug 18, 2014.;
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)